Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML
Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.
Amir Fathi Resistance Profile Menin Inhibitor Ziftomenib Adults With Acute Myeloid Leukemia Npm1 Mutations
Source: onclive.com